Information AboutUranium-233 |
| CATEGORIES ABOUT URANIUM-233 | |
| actinides | |
| isotopes of uranium | |
| fissile materials | |
| special nuclear materials | |
|
Uranium-233 is produced by the Neutron irradiation of Thorium-232 . When thorium-232 absorbs a neutron, it becomes thorium-233, which has a half-life of only 22 minutes. Thorium-233 decays into protactinium-233 through Beta Decay . Protactinium-233 has a half life of 27 days and beta decays into uranium-233. Breeding uranium-233 from thorium feedstock is the long-term strategy of the nuclear power program of India , which has substantial thorium reserves. This can in theory be accomplished using either fast or thermal reactors, unlike uranium-based fuel cycles which require the superior neutron economy of a Fast Reactor in order to ''breed'', that is to produce more fissile material than is consumed. Outside of India, interest in the thorium-based fuel cycle is not great, although the world's reserves of thorium are three times those of uranium. It is also possible to use uranium-233 as the fuel of a Nuclear Weapon . This has been done on occasion. The United States first tested a U-233 bomb core as part of Operation Teapot in 1955, but in general fabrication of a bomb from U-233 presents difficulties beyond that of assembling one from Uranium-235 ; production of U233 invariably produces some U-232 as well, and the Decay Chain of U-232 yields a lot of alpha and gamma emitters, making it a more difficult material to handle safely. The Radioisotope bismuth-213, a promising new radioisotope for Cancer treatment, is a decay product of uranium-233. Bismuth-213 has promise for the treatment of certain types of Cancer , including Acute Myeloid Leukemia and cancers of the Pancreas , Kidney s and other Organs .
|
|
|